KDM5B‑mediated H3K4me3 demethylation at STING regulators dictates senescent cell negotiator phenotype

Chloe Vargas (PhD)· Mar 23, 2026

Hypothesis

KDM5B activity sets the immunogenic state of senescent cells by demethylating H3K4me3 at promoters of genes that restrain the cGAS‑STING pathway. When KDM5B is active, H3K4me3 levels at these loci stay low, keeping TREX1, DNase2 and other STING antagonists expressed, which dampens interferon signaling and yields a SASP rich in tissue‑repair factors. Loss of KDM5B leads to H3K4me3 accumulation at the same promoters, silencing antagonists, unleashing STING‑TBK1‑IRF3 signaling and shifting the SASP toward a pro‑inflammatory, immunogenic profile that recruits immune clearance.

Mechanistic Reasoning

Chromatin gatekeeping – KDM5B removes activating H3K4me3 marks. Recent work shows histone methylation balance gates whether cells broadcast danger signals or stay immunologically silent (KDM5 histone demethylases suppress cGAS‑STING).
Target loci – Bioinformatic analysis of senescent fibroblast ATAC‑seq and ChIP‑seq datasets predicts KDM5B binding near TREX1, DNase2 and IFI16 promoters, all negative regulators of cytosolic DNA sensing.
Signal output – Low antagonist expression permits cGAS activation by self‑DNA, driving TBK1‑IRF3‑dependent IFN‑β production and NF‑κB‑dependent SASP components (IL‑6, IL‑8). High antagonist expression blocks this cascade, favoring a SASP enriched in TGF‑β, VEGF and IGF‑1 that supports tissue remodeling without strong immune recruitment.
Negotiator switch – Thus senescent cells can toggle between a “repair‑negotiator” mode (high KDM5B activity) and an “alarm‑negotiator” mode (low KDM5B activity) depending on metabolic cues, oxidative stress or drug exposure that modulate KDM5B expression or activity.

Testable Predictions

Prediction 1: Knockdown or pharmacological inhibition of KDM5B in oncogene‑induced senescent cells will increase H3K4me3 at TREX1 and DNase2 promoters, reduce their mRNA/protein levels, and potentiate cGAS‑STING‑IFN signaling.
Prediction 2: This epigenetic shift will convert the SASP from a repair‑biased profile (high TGF‑β, low IL‑6) to an immune‑biased profile (high IFN‑β, IL‑6, CXCL10).
Prediction 3: In vivo, transient KDM5B inhibition before senolytic treatment will enhance immune clearance of senescent cells and reduce tumor recurrence in models of liver fibrosis, whereas KDM5B overexpression will impair clearance and promote persistence of a pro‑tumorigenic SASP.

Experimental Approach

Cellular models – Use IMR90 fibroblasts subjected to irradiation‑induced senescence and KRAS^G12V‑induced oncogenic senescence. Treat with KDM5B siRNA, CRISPRi, or the small‑molecule inhibitor CPI-455.
Epigenetic profiling – Perform CUT&RUN for H3K4me3 and KDM5B at predicted promoter regions; validate changes by qPCR.
Pathway readouts – Measure cytosolic DNA (cGAS‑binding assay), phosphorylated TBK1/IRF3, IFN‑β ELISA, and NF‑κB luciferase activity.
SASP quantification – Deploy multiplex cytokine arrays (Luminex) and mass‑spectrometry‑based secretome analysis to categorize repair vs. immune signatures.
In vivo validation – Employ a p16‑3MR mouse model of liver fibrosis; administer KDM5B inhibitor or vehicle prior to navitoclax senolytic. Assess senescent cell burden (p16^INK4a^ immunostaining), immune infiltrates (flow cytometry for CD8^+, NK1.1^+), and fibrosis scores (Sirius Red).
Rescue experiments – Overexpress TREX1 or DNase2 in KDM5B‑deficient senescent cells to test whether restoring antagonist expression normalizes STING signaling and SASP composition.

Potential Outcomes and Interpretation

If KDM5B loss increases H3K4me3 at antagonist loci, silences their expression, and amplifies STING‑dependent IFN signaling while shifting the SASP toward inflammatory cytokines, the hypothesis is supported.
If SASP composition remains unchanged despite epigenetic alterations, or if immune clearance is not enhanced in vivo, the hypothesis would be refuted, suggesting that KDM5B regulates senescence through alternative pathways (e.g., metabolic or ribosomal control).
A partial effect (e.g., increased IFN‑β but no change in IL‑6) would indicate that KDM5B tunes specific arms of the negotiator repertoire, prompting refinement of the model to include co‑regulators such as KDM6B or HDACs.

This framework directly links epigenetic enzyme activity to the functional duality of senescent cells as negotiators, offering a clear, falsifiable route to evaluate whether manipulating KDM5B can tilt the balance between tissue repair and immune surveillance.

Hypothesis

Mechanistic Reasoning

Chromatin gatekeeping – KDM5B removes activating H3K4me3 marks. Recent work shows histone methylation balance gates whether cells broadcast danger signals or stay immunologically silent (KDM5 histone demethylases suppress cGAS‑STING).

Target loci – Bioinformatic analysis of senescent fibroblast ATAC‑seq and ChIP‑seq datasets predicts KDM5B binding near TREX1, DNase2 and IFI16 promoters, all negative regulators of cytosolic DNA sensing.

Signal output – Low antagonist expression permits cGAS activation by self‑DNA, driving TBK1‑IRF3‑dependent IFN‑β production and NF‑κB‑dependent SASP components (IL‑6, IL‑8). High antagonist expression blocks this cascade, favoring a SASP enriched in TGF‑β, VEGF and IGF‑1 that supports tissue remodeling without strong immune recruitment.

Negotiator switch – Thus senescent cells can toggle between a “repair‑negotiator” mode (high KDM5B activity) and an “alarm‑negotiator” mode (low KDM5B activity) depending on metabolic cues, oxidative stress or drug exposure that modulate KDM5B expression or activity.

Testable Predictions

Prediction 1: Knockdown or pharmacological inhibition of KDM5B in oncogene‑induced senescent cells will increase H3K4me3 at TREX1 and DNase2 promoters, reduce their mRNA/protein levels, and potentiate cGAS‑STING‑IFN signaling.

Prediction 2: This epigenetic shift will convert the SASP from a repair‑biased profile (high TGF‑β, low IL‑6) to an immune‑biased profile (high IFN‑β, IL‑6, CXCL10).

Prediction 3: In vivo, transient KDM5B inhibition before senolytic treatment will enhance immune clearance of senescent cells and reduce tumor recurrence in models of liver fibrosis, whereas KDM5B overexpression will impair clearance and promote persistence of a pro‑tumorigenic SASP.

Experimental Approach

Cellular models – Use IMR90 fibroblasts subjected to irradiation‑induced senescence and KRAS^G12V‑induced oncogenic senescence. Treat with KDM5B siRNA, CRISPRi, or the small‑molecule inhibitor CPI-455.

Epigenetic profiling – Perform CUT&RUN for H3K4me3 and KDM5B at predicted promoter regions; validate changes by qPCR.

Pathway readouts – Measure cytosolic DNA (cGAS‑binding assay), phosphorylated TBK1/IRF3, IFN‑β ELISA, and NF‑κB luciferase activity.

SASP quantification – Deploy multiplex cytokine arrays (Luminex) and mass‑spectrometry‑based secretome analysis to categorize repair vs. immune signatures.

In vivo validation – Employ a p16‑3MR mouse model of liver fibrosis; administer KDM5B inhibitor or vehicle prior to navitoclax senolytic. Assess senescent cell burden (p16^INK4a^ immunostaining), immune infiltrates (flow cytometry for CD8^+, NK1.1^+), and fibrosis scores (Sirius Red).

Rescue experiments – Overexpress TREX1 or DNase2 in KDM5B‑deficient senescent cells to test whether restoring antagonist expression normalizes STING signaling and SASP composition.

Potential Outcomes and Interpretation

If KDM5B loss increases H3K4me3 at antagonist loci, silences their expression, and amplifies STING‑dependent IFN signaling while shifting the SASP toward inflammatory cytokines, the hypothesis is supported.

If SASP composition remains unchanged despite epigenetic alterations, or if immune clearance is not enhanced in vivo, the hypothesis would be refuted, suggesting that KDM5B regulates senescence through alternative pathways (e.g., metabolic or ribosomal control).

A partial effect (e.g., increased IFN‑β but no change in IL‑6) would indicate that KDM5B tunes specific arms of the negotiator repertoire, prompting refinement of the model to include co‑regulators such as KDM6B or HDACs.